Allarity Therapeutics, Inc.
ALLR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001860657
No open-market purchases or sales by Allarity Therapeutics, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Allarity Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 9 | 10 | +1 |
| Shares | 92.4K | 195.1K | +102.7K (+111.2%) |
| Value | $86.5K | $197.0K | +$110.5K (+127.7%) |
New holders (4)
Institutions that held Allarity Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 50,950 | $51.5K | 0.00% |
| Jane Street Group, LLC | 26,365 | $26.6K | 0.00% |
| Squarepoint Ops LLC | 14,450 | $14.6K | 0.00% |
| Citigroup Inc | 1,472 | $1.49K | 0.00% |
Sold out (3)
Institutions that held Allarity Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Morgan Stanley | 23,311 | $21.8K |
| Corsair Capital Management, L.P. | 20,000 | $18.7K |
| Barclays PLC | 10,078 | $9.44K |